Researcher

Ms Brooke Anne Pereira

Biography

Brooke completed her PhD at Monash University within the Biomedicine Discovery Institute (BDI) under the supervision of Professor Gail Risbridger in early 2019. During her candidature she studied tumour-stroma interactions in localised prostate cancer using tissue engineering and quantitative mass spectrometry (MS)-based proteomics. Brooke is now a post-doctoral Research Officer at the Garvan Institute of Medical Research, where she is...view more

Brooke completed her PhD at Monash University within the Biomedicine Discovery Institute (BDI) under the supervision of Professor Gail Risbridger in early 2019. During her candidature she studied tumour-stroma interactions in localised prostate cancer using tissue engineering and quantitative mass spectrometry (MS)-based proteomics. Brooke is now a post-doctoral Research Officer at the Garvan Institute of Medical Research, where she is investigating novel stromal targets in pancreatic cancer under the supervision of Associate Professor Paul Timpson. She is using a range of cutting-edge techniques such as patient-derived xenografting (PDX), LC-MS/MS, MALDI imaging and advanced microscopy to study the stroma of both murine and human pancreatic tumours. Brooke is a Conjoint Associate Lecturer in the Faulty of Medicine at UNSW.


My Grants

2020 – 2021    Sydney Catalyst Seed Funding Grant - CIA Brooke Pereira. Dual targeting of stromal and immunological aberrations in pancreatic cancer by combining perlecan inhibition with immunotherapy. ($50,000 AUD)


My Qualifications

PhD - 2019 - Monash University Australia
BS/BEng (Hons) - 2013 - Monash University Australia


My Awards

Awards/Honours
2018 Lorne Cancer Conference Poster Prize – 1 of 6 awarded
2017 EACR Image of the Month – “3D melt electrospun scaffold model of the human prostate tumour microenvironment” http://magazine.eacr.org/eacr-image-of-the-month-october-2016-2017/4/
2016 World Biomaterials Congress (WBC) Trainee Award – 1 of 45 recipients worldwide
2014 ASMR Campion-Ma-Playoust Memorial Award – Best Presentation at the Australian Health and Medical Research Congress
2014 Department of Education Research Training Program (RTP) PhD Stipend
2013 Monash Summer Research Scholarship – Australian Centre of Blood Diseases (ACBD)

Travel Grants
2017 ESA Postgraduate Student Travel Grant
2017 ASBTE Postgraduate Student Travel Grant
2016 Monash University Postgraduate Travel Grant Award
2016 ASBTE Postgraduate Student Travel Grant
2015 Monash Institute for Medical Engineering (MIME) Travel Grant
2014 Justus Liebig University (JLU) Postgraduate Student Travel Grant


My Research Activities

Journal Articles (Published)

  1. Lawrence MG*, Pidsley R*, Niranjan B, Papargiris MM, Pereira BA, Richards M, Teng L, Norden S, Ryan A, Frydenberg M, Stirzaker C, Taylor RA, Risbridger GP, Clark SJ (* contributed equally) “Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer" 12, 48 (* contributed equally) DOI: 10.1186/s13148-020-00836-2 (2020) Clinical Epigenomics

 

  1. Ritchie SC, Pereira BA, Vennin C*, Timpson P* “Targeting genetically-tuned CAFs in pancreatic cancer via perlecan manipulation” (* contributed equally) DOI: 10.1080/14728222.2020.1727887 (2020) Expert Opinion on Therapeutic Targets (Commissioned)

 

  1. Pereira BA^, Vennin C^, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, Cox TR*, Timpson P* “CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer”. DOI: 10.1016/j.trecan.2019.1009.1010 (^, * contributed equally) (2019) Trends in Cancer (Co-First Author)

 

  1. Nguyen EV*, Pereira BA*, Lawrence MG, Rebello RJ, Chan H, Niranjan B, Skhinas JN, Cox TR, Risbridger GP, Taylor RA^, Lister NL^ & Daly RJ^ “Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment”. mcp.RA119.001496. (^,* contributed equally) (2019) Molecular & Cellular Proteomics (Co-First Author)

 

  1. Pereira BA, Hashimoto K, Lister NL, Teng L, Flandes-Iparraguirre M, Eder A, Sanchez-Herrero A, Niranjan B, Melbourne Urological Research Alliance (MURAL), Frydenberg M, Papargiris MM, Lawrence MG, Taylor RA, Hutmacher DW, Ellem SJ*, Risbridger GP*, De-Juan-Pardo EM* “Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro” 197:72-85. (* contributed equally) (2019) Biomaterials (First Author)

 

  1. Pereira BA, Lister NL, De-Juan-Pardo EM, Risbridger GP & Ellem SJ “5.17 Three-Dimensional Bioengineered Cancer Models” Oxford, Elsevier: 303-328 (2017) Comprehensive Biomaterials (2nd Edition) (Commissioned and First Author)

 

  1. Hutmacher DW, Holzapfel BM, De-Juan-Pardo EM, Pereira BA, Ellem SJ, Loessner D and Risbridger GP "Convergence of regenerative medicine and synthetic biology to develop standardized and validated models of human diseases with clinical relevance." 35(0):127-132. (2015) Current Opinion in Biotechnology (Commissioned)

 

  1. Kolodziejczyk B, Winther-Jensen O, Pereira BA, Nair SS and Winther-Jensen O "Patterning of conducting layers on breathable substrates using laser engraving for gas sensors." 132: 42359. (2015) Journal of Applied Polymer Science

 

Journal Articles (Published as APGI Consortium Member)

  1. Castillo L, Young AIJ, Mawson A, Schafranek P, Steinmann AM, Nessem D, Parkin A, Johns A, Chou A, Law AMK, Lucas MC, Murphy KJ, Deng N, Gallego-Ortega D, Caldon CE, Australian Pancreatic Cancer Genome (APGI)*, Timpson P, Pajic M, Ormandy CJ, Oakes SR “MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma” DOI: 10.1038/s41388-019-1091-0 (2019) Oncogene  *Pereira BA as APGI consortium member

 

  1. Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian  A, Grey S, Silva AD, Leung W, Australian Pancreatic Cancer Genome Initiative (APGI)*, Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips, PA, Whitelock, JM, Gill AJ., Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR & Timpson P “CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan”. 10(1): p. 3637. (2019) Nature Communications *Pereira BA as APGI consortium member
View less